Full-text search

Results for “Synageva Biopharma”

Search across the indexed text of every released document.

Names that match “Synageva Biopharma”

9 documents found

Times Square Tower
document TEXT-001-HOUSE_OVERSIGHT_024003.txt House Oversight Committee — Epstein Estate Records (Nov 2025)

…g or terminating investments into others. Examples of this type of investment include Intarcia Therapeutics (NLV-I) and Synageva Biopharma (NLV-II, reverse merger to become public – November, 2011, NASDAQ: GEVA; exited at 7.3x). Restructuring & Recapitalizing Public Companies: Th...

Leadership: NLV_ are leaders in biopharmaceutical investing across all stages and transaction
document IMAGES-007-HOUSE_OVERSIGHT_024045.txt House Oversight Committee — Epstein Estate Records (Nov 2025)

…g or terminating investments into others. Examples of this type of investment include Intarcia Therapeutics (NLV-I) and Synageva Biopharma (NLV-II, reverse merger to become public - November, 2011, NASDAQ: GEVA,; exited at 7.3x). e Restructuring & Recapitalizing Public Companies...

For the last several decades the healthcare venture capital industry has been the predominant
document IMAGES-007-HOUSE_OVERSIGHT_024040.txt House Oversight Committee — Epstein Estate Records (Nov 2025)

CONTRACTION IN HEALTHCARE VENTURE CAPITAL INDUSTRY & CAPITAL MARKET DYNAMICS MORE BROADLY CREATE OPPORTUNITY IN DEVELOPMENT STAGE AND EARLY COMMERCIAL STAGE COMPANIES For the last several decades the healthcare venture capital industry has been the predominant source of early an...

The Fund Managers have a proactive approach to deal sourcing, which focuses on both private
document IMAGES-007-HOUSE_OVERSIGHT_024054.txt House Oversight Committee — Epstein Estate Records (Nov 2025)

VI. DEAL SOURCING & INVESTMENT PROCESS The Fund Managers have a proactive approach to deal sourcing, which focuses on both private and public opportunities. The established and proven sourcing activities seek to identify the most compelling healthcare technology investment oppor...

Capital Markets for Cannabis Companies
document IMAGES-008-HOUSE_OVERSIGHT_024761.txt House Oversight Committee — Epstein Estate Records (Nov 2025)

ACKRELL CAPITAL CHAPTER VII Capital Markets for Cannabis Companies Over The Counter (Market Value Greater than $25 million) Enterprise Value (EV) LTM Revenue LTM LTM EV Multiples EBITDA Revenue EBITDA ($U.S. millions, except stock price) Stock % Below Price 52-Week Mark...

NLV-III will be managed by the New Leaf team, which currently manages NLV-I, NLV-IL, and
document IMAGES-007-HOUSE_OVERSIGHT_024022.txt House Oversight Committee — Epstein Estate Records (Nov 2025)

Il. THE TEAM NLV-III will be managed by the New Leaf team, which currently manages NLV-I, NLV-IL, and provides sub-advisory services managing the remaining healthcare technology investments in the Sprout Funds. The team of six senior partners, five of whom have worked together c...

¢ Gabi, a San Francisco-based insurance shopping services, has raised $9.5 million in
document IMAGES-006-HOUSE_OVERSIGHT_021101.txt House Oversight Committee — Epstein Estate Records (Nov 2025)

¢ Gabi, a San Francisco-based insurance shopping services, has raised $9.5 million in Series A funding led by Canvas Ventures, with participation from Correlation Ventures, Northwestern Mutual Future Ventures, Securian Ventures, A.Capital Ventures and Project A. www.gabi.com ¢ D...

James Niedel, MD, Ph.D., (70), Venture Partner, joined Sprout in May 2002 and helped found
document IMAGES-007-HOUSE_OVERSIGHT_024024.txt House Oversight Committee — Epstein Estate Records (Nov 2025)

James Niedel, MD, Ph.D., (70), Venture Partner, joined Sprout in May 2002 and helped found New Leaf in 2005. Jim will change his status to Venture Partner in NLV-II] with the closing of the new fund. In this role, Jim will work full-time as a senior member of the NLV investment t...

Vitality Biopharma
document Vitality Biopharma House Oversight Committee — Epstein Estate Records (Nov 2025)

Inc. OTCQB:VBIO 1.85 56.4% 42.7 41.9 0.1 –4.3 NM NM